| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Thyrotropin-releasing hormone-degrading ectoenzyme, TRH-DE, TRH-degrading ectoenzyme, Pyroglutamyl-peptidase II, PAP-II, TRH-specific aminopeptidase, Thyroliberinase, TRHDE |
| Entrez GeneID | 29953 |
| WB Predicted band size | 117.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This TRHDE antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 951-980 amino acids from the C-terminal region of human TRHDE. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于TRHDE抗体的模拟参考文献示例(请注意，这些文献为虚构示例，实际研究中请通过学术数据库查询真实文献)：
---
1. **文献名称**: *Development and Application of a TRHDE-Specific Monoclonal Antibody for Thyroid Function Studies*
**作者**: Smith A, et al.
**摘要**: 本研究开发了一种高特异性的TRHDE单克隆抗体，用于探究TRH降解酶(TRHDE)在调节促甲状腺激素释放激素(TRH)水平中的作用。通过体外实验和小鼠模型，发现抗体抑制TRHDE活性后可显著提升血清TRH浓度，进而影响下游甲状腺激素(T3/T4)的分泌，提示TRHDE可能成为甲状腺功能异常的潜在治疗靶点。
---
2. **文献名称**: *TRHDE Antibodies in Neurological Disorders: Implications for TRH-Mediated Neuroprotection*
**作者**: Chen L, et al.
**摘要**: 该研究探讨了TRHDE抗体在中枢神经系统疾病中的潜在应用。通过免疫组化与脑脊液分析，发现阿尔茨海默病模型小鼠中TRHDE表达上调，而使用TRHDE抗体阻断其活性可减少TRH降解，增强神经保护作用并改善认知功能，表明TRHDE抗体或对神经退行性疾病具有治疗价值。
---
3. **文献名称**: *A Novel TRHDE Polyclonal Antibody for Diagnostic Assays in Hypothalamic-Pituitary Dysfunction*
**作者**: Gupta R, et al.
**摘要**: 研究团队制备了一种TRHDE多克隆抗体，并验证其在诊断下丘脑-垂体轴功能障碍中的实用性。通过ELISA和免疫印迹法，该抗体能精准检测人血清中TRHDE水平，临床样本分析显示TRHDE异常升高与甲状腺功能减退症相关，支持其作为新型生物标志物的潜力。
---
4. **文献名称**: *TRHDE Knockdown via Antibody-Based Targeting Alters Metabolic Homeostasis in Obese Models*
**作者**: Tanaka K, et al.
**摘要**: 本研究利用TRHDE中和抗体靶向抑制肥胖小鼠模型中的TRHDE活性，发现TRH水平升高可促进能量代谢并改善胰岛素敏感性。结果提示，TRHDE抗体可能通过调节TRH通路影响代谢综合征相关病理过程。
---
建议通过 **PubMed**、**Web of Science** 或 **Google Scholar** 检索关键词如“TRHDE antibody”、“TRH-degrading enzyme”或“TRHDE function”以获取真实文献。
TRHDE (thyrotropin-releasing hormone degrading enzyme) antibodies are tools used in research to study the enzyme’s role in regulating thyrotropin-releasing hormone (TRH), a key neuropeptide involved in the hypothalamic-pituitary-thyroid axis. TRHDE, also known as pyroglutamyl peptidase II, is a membrane-bound metalloenzyme that inactivates TRH by cleaving its N-terminal pyroglutamate residue. This degradation process modulates TRH availability, influencing thyroid-stimulating hormone (TSH) release and downstream thyroid hormone production. Dysregulation of TRHDE activity has been linked to endocrine disorders, neurological conditions, and metabolic imbalances.
Antibodies targeting TRHDE enable the detection and localization of the enzyme in tissues, particularly the brain, pituitary gland, and thyroid. They are critical for investigating TRHDE’s expression patterns, enzymatic activity, and interactions in cellular or animal models. Recent studies explore TRHDE’s potential involvement in neurodegenerative diseases (e.g., Alzheimer’s) due to its role in neuropeptide metabolism, as well as its impact on energy homeostasis and appetite regulation. Commercially available TRHDE antibodies are typically validated for techniques like Western blotting, immunohistochemistry, or ELISA. However, challenges remain in standardizing antibody specificity across species, given structural similarities with other peptidases. Ongoing research aims to clarify TRHDE’s therapeutic potential as a drug target for thyroid dysfunction or neurological disorders.
×
